The Beginning of a "Regulatory Renaissance": Positioning Regulatory Coverage at the Interface of Human Expertise and Digital Support.

Ther Innov Regul Sci

U.S. Food and Drug Administration, White Oak Campus 10903 New Hampshire Ave, Silver Spring, Maryland, MD, 20993, USA.

Published: March 2025

Following the largest reorganization in its history, the U.S. Food and Drug Administration (FDA) is now working to modernize how it defines and engages in regulatory oversight of the quality of products that the agency regulates. However, the volume and complexity of these tasks, coupled with the size and interdependent nature of the global supply chains that generate and distribute these products, raise questions about how the agency can keep up with the pace of change. This dilemma, together with the FDA's recent reorganization, create an opportunity to rethink the FDA's strategy for regulatory coverage and usher in a "regulatory renaissance." In this article, we examine how the agency is working to develop a more quantitative, comprehensive approach to ensuring that the wide arrays of FDA-regulated commodities are produced and distributed in systems that meet societal expectations for safety and quality in a global digital environment. We discuss a number of tools and methods that the agency can bring to bear to achieve this goal, including leveraging internal FDA data and information from third-party audits; utilizing information from foreign regulators; incorporating data and findings from state and local inspections; and applying sophisticated data technologies including AI systems. The underlying concept for this regulatory renaissance is for the agency to focus on leveraging multiple sources of data, information, and analysis to inform its actions in order to optimize the quality of products produced by regulated industries, including the dimensions of safety, effectiveness, and reliability of manufacturing, as well as distribution and instructions for use throughout their product lifecycle. The degree of success of this approach will depend upon a broad recognition of similar opportunities across the regulated industries, sister federal and state agencies, and academia working on regulatory science.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s43441-025-00745-7DOI Listing

Publication Analysis

Top Keywords

"regulatory renaissance"
8
regulatory coverage
8
quality products
8
regulated industries
8
regulatory
5
agency
5
renaissance" positioning
4
positioning regulatory
4
coverage interface
4
interface human
4

Similar Publications

The Beginning of a "Regulatory Renaissance": Positioning Regulatory Coverage at the Interface of Human Expertise and Digital Support.

Ther Innov Regul Sci

March 2025

U.S. Food and Drug Administration, White Oak Campus 10903 New Hampshire Ave, Silver Spring, Maryland, MD, 20993, USA.

Following the largest reorganization in its history, the U.S. Food and Drug Administration (FDA) is now working to modernize how it defines and engages in regulatory oversight of the quality of products that the agency regulates.

View Article and Find Full Text PDF

Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.

Eur Psychiatry

January 2025

Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium.

Background: Recent years show an exponential increased interest ("renaissance") in the use of psychedelics for the treatment of mental disorders and broader. Some of these treatments, such as psilocybin for depression, are in the process of formal regulation by regulatory bodies in the US (FDA) and Europe (EMA), and as such on the brink of real-world implementation. In the slipstream of these developments increasing commercial initiatives are taking shape.

View Article and Find Full Text PDF
Article Synopsis
  • Significant advances in cancer treatment have led to new options in chemotherapy, radiotherapy, immunotherapy, and targeted therapies, but resistance to these treatments often leads to tumor recurrence and poorer survival rates.
  • Tumor cells utilize multiple mechanisms to develop resistance to anticancer drugs, and current efforts to combat this resistance have seen limited success.
  • The review focuses on the role of mA RNA modification dysregulation in cancer therapy resistance, exploring recent studies and the potential of targeting these modifications to improve treatment outcomes.
View Article and Find Full Text PDF

Basal cell carcinoma (BCC), the most prevalent form of human cancer, is traditionally treated by surgical and alternative destructive or topical chemical means, each with its advantages, challenges, and drawbacks. We describe our experience treating BCCs with a topical concentrate of proteolytic enzymes enriched in bromelain (CPEEB) sourced from pineapple stems. CPEEB has strong proteolytic, antitumor-proapoptotic, and inflammation modulation activities, and is approved for debridement of deep burns and starting phase 3 trials for chronic wounds.

View Article and Find Full Text PDF

We used marker-free technologies to study chromatin at cellular resolution. Our results show asymmetric chromatin distribution, explore chromatin dynamics during mitosis, and reveal structural differences between trichoblast and atrichoblast cell. The shapes, sizes, and structural organizations of plant nuclei vary considerably among cell types, tissues, and species.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!